|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.280 SEK | -3.80% |
|
-2.15% | +0.88% |
| 04-21 | Larkberget to carry out rights issue of units totaling SEK 14.9 mln | RE |
| 04-17 | Larkberget net asset value per share at SEK 3.04 | RE |
Company Valuation: CombiGene AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 157.3 | 225.7 | 180.9 | 53.27 | 47.13 | 44.75 |
| Change | - | 43.52% | -19.87% | -70.55% | -11.52% | -5.04% |
| Enterprise Value (EV) 1 | 108.4 | 88.99 | 49.11 | -48.17 | -26.62 | 38.91 |
| Change | - | -17.9% | -44.82% | -198.1% | 44.74% | 246.16% |
| P/E | -4.17x | 9.42x | -29.4x | -1.49x | -1.05x | -3.62x |
| PBR | 2.2x | 1.43x | 1.19x | 0.46x | 0.66x | 0.81x |
| PEG | - | -0x | 0x | -0x | -0x | 0x |
| Capitalization / Revenue | 14.5x | 2.48x | 6.3x | 7.6x | 23.6x | 147x |
| EV / Revenue | 10x | 0.98x | 1.71x | -6.87x | -13.3x | 128x |
| EV / EBITDA | -4.45x | 3.84x | -2.83x | 1.34x | 0.83x | -5.41x |
| EV / EBIT | -4.03x | 3.89x | -2.78x | 1.33x | 0.7x | -3x |
| EV / FCF | -3.73x | 6.84x | -4.04x | 2.57x | 1.54x | -3.65x |
| FCF Yield | -26.8% | 14.6% | -24.7% | 39% | 65.1% | -27.4% |
| Dividend per Share 2 | - | - | - | - | 0.2 | 2 |
| Rate of return | - | - | - | - | 8.4% | 88.5% |
| EPS 2 | -3.287 | 1.21 | -0.3109 | -1.801 | -2.27 | -0.6242 |
| Distribution rate | - | - | - | - | -8.81% | -320% |
| Net sales 1 | 10.83 | 91.15 | 28.73 | 7.008 | 1.999 | 0.304 |
| EBITDA 1 | -24.37 | 23.19 | -17.36 | -35.98 | -32.12 | -7.187 |
| EBIT 1 | -26.87 | 22.89 | -17.66 | -36.31 | -37.92 | -12.98 |
| Net income 1 | -29.38 | 20.96 | -6.157 | -35.67 | -44.88 | -12.36 |
| Net Debt 1 | -48.9 | -136.7 | -131.8 | -101.4 | -73.75 | -5.842 |
| Reference price 2 | 13.720 | 11.400 | 9.135 | 2.690 | 2.380 | 2.260 |
| Nbr of stocks (in thousands) | 11,464 | 19,801 | 19,801 | 19,801 | 19,801 | 19,801 |
| Announcement Date | 5/4/21 | 4/27/22 | 4/26/23 | 4/26/24 | 5/12/25 | 4/2/26 |
1SEK in Million2SEK
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 4.65M | |
| 34.2x | 8.53x | 26.72x | 0.05% | 55.63B | |
| 19.78x | 6x | 13.04x | 1.52% | 52.25B | |
| -18.16x | 4.33x | -7.56x | -.--% | 23.07B | |
| -39.15x | 12.94x | -37.74x | -.--% | 22.41B | |
| 21.62x | 4.23x | 10.97x | -.--% | 17.32B | |
| 22.36x | 4.48x | 14.84x | -.--% | 15.94B | |
| 17.25x | 5x | 11.74x | -.--% | 13.77B | |
| 44.46x | 16.86x | 51x | -.--% | 13.47B | |
| -436.4x | 29.85x | -3327.81x | -.--% | 12.43B | |
| Average | -37.12x | 10.25x | -360.53x | 0.18% | 22.63B | |
| Weighted average by Cap. | -9.80x | 8.79x | -172.08x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LARK Stock
- Valuation CombiGene AB
Select your edition
All financial news and data tailored to specific country editions
